课题基金 / 基金详情

Combination Gene Therapy and Th1Th2 Therapy

Combination Gene Therapy and Th1Th2 Therapy
联合基因疗法和 Th1Th2 疗法
批准号：
7966240
负责人：
DANIEL FOWLER
金额：
$32.56万
依托单位：
DIVISION OF BASIC SCIENCES - NCI
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/7966240
关键词：
AgreementAllogenicAnimal ModelApoptosisCell TherapyCell physiologyCellsClinical ProtocolsComplicationEnvironmentEnzymesGene DeliveryGene TransferGenesGoalsHematopoietic Stem Cell TransplantationLentivirus VectorModelingMutateProdrugsProteinsResearchResistanceSafetySirolimusSuicideT-LymphocyteTestingTherapeuticTissuesUniversitiesWorkZidovudinecombination gene therapygene therapygraft vs host diseaseimmuno-gene therapyimprovedin vivomedinnovelsuicide genetherapeutic genetumor

项目摘要

项目成果

DANIEL FOWLER的其他基金

相似基金

相关文献

中文摘要
翻译
我们的工作重点是使用慢病毒载体将基因转移到 雷帕霉素抗性T细胞。使用这种方法，给定培养物中的大多数T细胞 可以被诱导表达新基因。我们还开发了动物模型来测试 这些免疫基因治疗策略的体内效应。这种模型包括肿瘤， 评估移植物抗宿主病，这仍然是同种异体移植后的主要并发症。 造血干细胞移植为配合这项计划的推行，我们 与Lentigen公司达成合作研究协议，开发临床 专注于自杀基因的慢病毒递送的方案。
英文摘要
We have focused our efforts on the use of lentiviral vectors to transfer genes to the rapamycin-resistant T cells. Using this approach, the majority of T cells in a given culture can be induced to express the new gene. We have also developed animal models to test the in vivo effect of these immuno-gene therapy strategies. Such models incorporate tumors and also evaluate graft-versus-host disease, which remains the main complication after allogeneic hematopoietic stem cell transplantation. To facilitate implementation of this project, we have entered into a cooperative research agreement with Lentigen Corporation to develop clinical protocols focusing on lentiviral delivery of suicide genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AUTOLOGOUS AND ALLOGENEIC T CELL STRATEGIES FOR HEMA C MALIGNANCY
Th1/Th2 & Tc1/Tc2 T Cell Subsets in Transplantation Ther
Autologous and Allogeneic T Cell Strategies for the Treatment of Hematologic Mal
Combination Gene Therapy and Th1Th2 Therapy
海外基金